Evaluate when the guidelines recommend GLP-1 RA use for T2D treatment. Review the glucose-dependent mechanism of action, safety, and dosing of a once-weekly GLP-1 RA.  Discuss the efficacy and safety data from pivotal T2D glycemic control trials and from the cardiovascular outcomes trial.

This content is developed exclusively by or on behalf of the industry sponsor through a third party and is not reviewed by Pri-Med. The content and opinions expressed are those of the sponsor or presenters and may not reflect the views of Pri-Med.



Pablo Mora, MD, FACE, MS Sc, CDE


North Texas Diabetes Center in Plano (Texas)

Clinical Professor of Medicine

Division of Endocrinology, Diabetes and Metabolism

University of Texas Southwestern Medical Center at Dallas

Dallas, Texas

Fine Print

The preferred browser is Google Chrome. If using a different browser, such as Safari, Firefox or Edge, make sure you are using the most up-to-date version. Your Internet settings should be set to accept cookies and JavaScript. If cookies and/or JavaScript are disabled, the site may not function properly. A high-speed Internet connection is not required; however, it is recommended for faster download times.